EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

An Update on Current Therapeutic Options in IgA Nephropathy

Regina Shaoying Lim, See Cheng Yeo iD, Jonathan Barratt, Dana V Rizk

Journal of Clinical Medicine · 07.02.2024 · 13 (4) · 947

DOI: 10.3390/jcm13040947 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 07.02.2024. Verfasst von Regina Shaoying Lim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Renal Medicine, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunoglobulin A nephropathy (IgAN) remains the leading cause of primary glomerular disease worldwide. Outcomes are poor with high rates of progressive chronic kidney disease and kidney failure, which contributes to global healthcare costs. Although this disease entity has been described, there were no disease-specific treatments until recently, with the current standard of care focusing on optimal supportive measures including lifestyle modifications and optimization of the renin-angiotensin-aldosterone blockade. However, with significant advances in the understanding of the pathogenesis of IgAN in the past decade, and the acceptance of surrogate outcomes for accelerated drug approval, there have been many new investigational agents tested to target this disease. As these agents become available, we envision a multi-pronged treatment strategy that simultaneously targets the consequences of ongoing nephron loss, stopping any glomerular inflammation, inhibiting pro-fibrotic signals in the glomerulus and tubulo-interstitium, and inhibiting the production of pathogenic IgA molecules. This review is an update on a previous review published in 2021, and we aim to summarize the developments and updates in therapeutic strategies in IgAN and highlight the promising discoveries that are likely to add to our armamentarium.

Schlagwörter

Stichwörter der Autor:innen

IgAIgA nephropathyclinical trialsglomerular diseasestherapytreatment

Autor:innen und Institutionen

  • Department of Renal Medicine, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
  • Department of Cardiovascular Sciences, University of Leicester, Leicester LE1 7RH, UK.
  • John Walls Renal Unit, University Hospitals of Leicester NHS Trust, Leicester LE5 4PW, UK.
  • Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, ZRB 614, 1720 2nd Avenue South, Birmingham, AL 35294, USA.

ORCID-Profile: See Cheng Yeo

Zitieren

APA

Lim, R. S., Yeo, S. C., Barratt, J., & Rizk, D. V. (2024). An Update on Current Therapeutic Options in IgA Nephropathy. Journal of Clinical Medicine, 13(4), 947. https://doi.org/10.3390/jcm13040947

Vancouver

Lim RS, Yeo SC, Barratt J, Rizk DV. An Update on Current Therapeutic Options in IgA Nephropathy. Journal of Clinical Medicine. 2024;13(4):947. doi:10.3390/jcm13040947

BibTeX
@article{Lim2024,
  author = {Lim, Regina Shaoying and Yeo, See Cheng and Barratt, Jonathan and Rizk, Dana V},
  title = {An Update on Current Therapeutic Options in IgA Nephropathy},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {4},
  pages = {947},
  doi = {10.3390/jcm13040947}
}
Kostenlos starten →